

Appendix A

**Timeline for ICCVAM Evaluation on Usefulness and Limitations
of the Murine Local Lymph Node Assay for Potency Categorization
of Chemicals Causing Allergic Contact Dermatitis in Humans**

This page intentionally left blank

ICCVAM Evaluation Timeline

- January 10, 2007** The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) receives a nomination from the Consumer Product Safety Commission (CPSC) to review the validation status of new versions and applications of the murine local lymph node assay (LLNA), including use of the LLNA for determining skin sensitization potency categories.¹
- January 2007** The ICCVAM interagency Immunotoxicity Working Group (IWG) is re-established to work with the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) to carry out the LLNA evaluations.
- January 24, 2007** ICCVAM endorses the CPSC-nominated LLNA review activities, including an evaluation on use of the LLNA for determining skin sensitization potency categories.
- May 17, 2007** *Federal Register* notice (72 FR 27815) – The Murine Local Lymph Node Assay: Request for Comments, Nominations of Scientific Experts, and Submission of Data
- June 12, 2007** The Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) endorses with high priority the CPSC-nominated LLNA review activities, including an evaluation on use of the LLNA for determining skin sensitization potency categories.
- January 8, 2008** *Federal Register* notice (73 FR 1360) – Announcement of an Independent Scientific Peer Review Panel Meeting on the Murine Local Lymph Node Assay; Availability of Draft Background Review Documents; Request for Comments
- March 4–6, 2008** Independent Scientific Peer Review Panel holds a public meeting with opportunity for oral public comments at CPSC headquarters in Bethesda, MD, to discuss LLNA review activities, including an evaluation on use of the LLNA for determining skin sensitization potency categories. The Panel is charged with reviewing the current status of the LLNA for potency use and commenting on the extent to which the information in the draft LLNA background review document supports the draft ICCVAM recommendations.²
- March 10–11, 2008** Organisation for Economic Co-operation and Development (OECD) Expert Meeting on Sensitization: Discussion of Globally Harmonized System of Classification and Labelling of Chemicals (GHS) hazard categories for skin sensitizers

¹ http://iccvam.niehs.nih.gov/methods/immunotox/llnadoocs/CPSC_LLNA_nom.pdf

² http://iccvam.niehs.nih.gov/methods/immunotox/llna_PeerPanel08.htm

May 20, 2008	<i>Federal Register</i> notice (73 FR 29136) – Peer Review Panel Report on the Validation Status of New Versions and Applications of the Murine Local Lymph Node Assay (LLNA): A Test Method for Assessing the Allergic Contact Dermatitis Potential of Chemicals and Products: Notice of Availability and Request for Public Comments
June 18–19, 2008	SACATM meeting: SACATM and public comments on the 2008 Panel report
July 2009	Publication of third revised edition of the GHS, which includes revised criteria for hazard classification and subcategories for skin sensitizers
July 2009 – August 2010	NICEATM performs additional analyses to evaluate the use of the LLNA for skin sensitization potency determinations based on comments from the independent scientific peer review panel, the public, and SACATM.
October 27, 2010	ICCVAM endorses the LLNA potency evaluation report, which includes ICCVAM’s recommendations and the final background review document on the validity of the LLNA for determining skin sensitization potency categories.
Winter 2011 (published within two weeks after transmittal)	<i>Federal Register</i> notice announces availability of the ICCVAM evaluation report on the usefulness and limitations of the LLNA for potency categorization of chemicals causing allergic contact dermatitis in humans.